Does daily high-potency cannabis use lead to more psychotic symptoms? | Research

The takeaway

The large EU-GEI study of 901 first-episode psychosis patients and 1,235 controls found a linear relationship between cannabis exposure and positive symptoms, with daily high-potency users showing the most severe positive symptoms and fewer negative symptoms.

Cannabis users concerned about psychosis risk, clinicians treating first-episode psychosis, and policymakers considering cannabis potency regulation.

901 patients across 6 countries

What the researchers found

In patients, daily high-potency cannabis use was associated with the highest positive symptom scores (B=0.35, 95% CI 0.14-0.56) in a dose-response pattern. Patients who never used cannabis had more negative symptoms than any cannabis-using group (B=-0.22, 95% CI -0.37 to -0.07). In controls, psychotic experiences correlated with current use but not lifetime exposure. No depression differences related to cannabis were found in either group.

Why it matters

This is the first large-scale evidence that cannabis potency and frequency interact to shape the symptom profile of first-episode psychosis. The dose-response relationship with positive symptoms strengthens the case for a causal contribution of cannabis to psychosis.

The numbers in context

901 FEP patients; 1,235 controls; 6 countries; daily high-potency use and positive symptoms B=0.35; never-use and negative symptoms B=-0.22; no association with depressive dimension

How the study worked

Cross-sectional case-control study from EU-GEI analyzing 901 FEP patients and 1,235 controls across six countries. Item response bifactor modeling generated symptom dimensions. Associations tested via linear mixed-effects models.

What this study cannot tell us

Cross-sectional design limits causal inference. Self-reported cannabis use patterns and potency. Potency definitions varied across countries. Patients were recruited after psychosis onset, so pre-illness cannabis patterns are retrospectively reported.

How to read the evidence

Large multicentric study with sophisticated statistical modeling, though cross-sectional design limits causal claims.

When this study was published

Published in 2021; EU-GEI remains one of the most comprehensive studies of cannabis and psychosis.

The bigger picture

The finding that cannabis use is associated with fewer negative symptoms alongside more positive symptoms may explain why some patients perceive cannabis as beneficial. They may experience reduced social withdrawal while their positive symptoms (hallucinations, delusions) actually worsen.

Questions still open

Could the inverse relationship with negative symptoms reflect self-medication for anhedonia? Would reducing cannabis potency through regulation change psychosis symptom profiles? Do these dose-response patterns inform prevention strategies?

Common questions

Does stronger cannabis cause worse psychosis?

This study found a dose-response relationship: daily use of high-potency cannabis was associated with the most severe positive symptoms, while occasional or low-potency use showed lesser associations.

Why might cannabis reduce negative symptoms?

Cannabis users had fewer negative symptoms (like social withdrawal and flat affect) compared to non-users. This could reflect self-medication, or it could mean that people with fewer negative symptoms are more socially engaged and thus more likely to use cannabis.

Read the original research

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.

Psychological medicine, 51(8), 1329-1337

View on PubMed ↗Publisher’s paper ↗

Citation

Quattrone, Diego; Ferraro, Laura; Tripoli, Giada; La Cascia, Caterina; Quigley, Harriet; Quattrone, Andrea; Jongsma, Hannah E; Del Peschio, Simona; Gatto, Giusy; Gayer-Anderson, Charlotte; Jones, Peter B; Kirkbride, James B; La Barbera, Daniele; Tarricone, Ilaria; Berardi, Domenico; Tosato, Sarah; Lasalvia, Antonio; Szöke, Andrei; Arango, Celso; Bernardo, Miquel; Bobes, Julio; Del Ben, Cristina Marta; Menezes, Paulo Rossi; Llorca, Pierre-Michel; Santos, Jose Luis; Sanjuán, Julio; Tortelli, Andrea; Velthorst, Eva; de Haan, Lieuwe; Rutten, Bart P F; Lynskey, Michael T; Freeman, Tom P; Sham, Pak C; Cardno, Alastair G; Vassos, Evangelos; van Os, Jim; Morgan, Craig; Reininghaus, Ulrich; Lewis, Cathryn M; Murray, Robin M; Di Forti, Marta. (2021). Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.. Psychological medicine, 51(8), 1329-1337. https://doi.org/10.1017/S0033291720000082